# The Topography of dopamine dysfunction in schizophrenia

#### Anissa Abi-Dargham MD

Professor of Psychiatry
Chief, Division of Translational Imaging
Columbia University
New York


Professor of Psychiatry
Vice Chair for Research
Department of Psychiatry
Stony Brook University
New York

#### OUTLINE

- The Hypothesis
- The Evidence
  - Confirming the hypothesis
  - Refining the hypothesis
  - Expanding the hypothesis
- The Model(s)
  - Is dopamine dysregulation a downstream effect of other more upstream events?
  - Or could it be more proximal than generally thought?

#### **OUTLINE**


- The Hypothesis/ background
- The Evidence
  - Confirming the hypothesis
  - Refining the hypothesis
  - Expanding the hypothesis
- The Model(s)
  - Is dopamine dysregulation a downstream effect of other more upstream events?
  - Or could it be more proximal than generally thought?



### Midbrain Regulation of DA neuron firing


|          | Frequency               | Basis                                       | Regulation   | Topography |
|----------|-------------------------|---|--|------------|
| Tonic    | 2-4 Hz                  | Pacemaker firing<br>Tonic synaptic<br>input | SK3, Ca <sup>2+</sup><br>channels<br>D2 autoreceptor | SN         |
| Bursting | 15-20 Hz<br>3-10 spikes | Excitatory input Inhibition of GABA input   | NMDA receptor  | VTA        |

## Reward prediction-error (rPE) signals



Schultz et al., O'Doherty et al., Daw et al., Glimcher et al.


#### **Basal ganglia circuits**




Gerfen CR, Surmeier DJ. 2011.

Annu. Rev. Neurosci. 34:441-66


# Dopamine modulates the balance of Excitation/ inhibition in the prefrontal cortex




#### JUVENILE



#### **ADULT**



#### ADULT with LOSS of INTERNEURON FUNCTION



O'Donnnell, SCZ bull, 2011

#### THE HYPOTHESIS

- Antipsychotic properties of chlorpromazine (Delay & Denicker, 1952)
- Dopamine turnover increased by antipsychotics (Carlsson & Lindqvist, 1963)
- Overstimulation of DA receptors in SCZ (Van Rossum, 1966)
- Dopamine-sensitive adenylyl cyclase (Greengard et al., 1972)
- Antipsychotic binding sites (Snyder et al.; Seeman et al., 1976)
- D1 and D2 dopamine receptors (Spano, 1978; Kebabian & Calne, 1979)
- DA agonists produce psychosis (Angrist and Van kammen 1984, Lieberman 1987)
- First formulation: mesolimbic DA excess
- Re-formulation of DA in SCZ: subcortical excess and cortical deficit (Weinberger 1987, Davis,1990)


#### OUTLINE

- The Hypothesis
- The Evidence
  - Confirming the hypothesis
  - Refining the hypothesis
  - Expanding the hypothesis
- The Model(s)
  - Is dopamine dysregulation a downstream effect of other more upstream events?
  - Or could it be more proximal than generally thought?

#### OUTLINE


- The Hypothesis
- The Evidence
  - Confirming the hypothesis
  - Refining the hypothesis
  - Expanding the hypothesis
- The Model(s)
  - Is dopamine dysregulation a downstream effect of other more upstream events?
  - Or could it be more proximal than generally thought?

#### Imaging the striatal dopaminergic synapse




## **Imaging Dopamine**

- D2 radiotracer
- Dopamine



## D2/3 PET imaging




[11C]raclopride

[11C]Fallypride

[11C]FLB457

#### STRIATAL dopamine alterations in schizophrenia




#### **Dopamine "synthesis"**

Reith et al., 1994 Hietala et al., 1995, 1999 Lindstorm et al., 1999 Meyer-Lindenberg et al., 2002 McGowan et al., 2004 Nozaki S et al., 2009 Howes et al., 2009


#### Dopamine "release"


- Amphetamine challenge -Laruelle et al., 1996 Breier et al., 1997 Abi-Dargham et al., 1998
- AMPT -Abi-Dargham et al., 2000 Kegeles et al., 2010

#### **D**<sub>2</sub> receptors




# Topography of STRIATAL DA alterations in striatal subdivisions:






#### Intrasynaptic dopamine in STR subdivisions in SCZ



#### Striatal Dopamine Release and Psychotic Symptoms



Change in Psychosis scores (PANSS)



# High Synaptic Dopamine Predicts Treatment Response at 6 Weeks






FIGURE 1. Mean Dopamine Synthesis Capacity for the Whole Striatum in Patients With Treatment-Resistant Schizophrenia, Treatment Responders, and Healthy Volunteers<sup>a</sup>




<sup>&</sup>lt;sup>a</sup> The treatment-resistant group showed significantly lower dopamine synthesis capacity than the treatment responders (p=0.02, corrected for multiple comparisons). There were no significant differences between treatment-resistant patients and healthy volunteers. Error bars indicate standard deviation.

Figure 4. Global Brain Connectivity of Striatal Subregions in Patients and Healthy Controls




Mean (SEM) absolute  $\beta$  values across all extrastriatal brain voxels are plotted by striatal subregion and group.


## Negative Symptoms inversely related to Dopamine Levels in Ventral Striatum



#### But not in the sensorimotor striatum




#### Striatal Dopamine Release and Psychotic Symptoms




Change in Psychosis scores (PANSS)

Thompson et al, Mol Psychiatry 2012




### Dopamine synthesis in the prodrome: [18F]f-DOPA increased in striatum



Howes et al, Arch Gen Psych 2009 Howes et al, Molecular Psych 2011 Howes et al, Am J Psychiatry 2011


# DA dysregulation is an early event, observed in the prodrome and predicts conversion




#### OUTLINE

- The Hypothesis
- The Evidence
  - Confirming the hypothesis
  - Refining the hypothesis: Associative striatum is affected
     » DA dysregulation precedes onset
  - Expanding the hypothesis:
  - The Model(s)
  - Is dopamine dysregulation a downstream effect of other more upstream events?
  - Or could it be more proximal than generally thought?

## **Cortical Dopamine in SCZ**




## D1 PET imaging




## PET studies of PFC D1 receptors in SCZ

| Study                    | Ligand        | n patients<br>(DN/DF) | n controls | Results                      |
|--------------------------|---------------|-----------------------|------------|------------------------------|
| Okubo et al.,<br>1997    | [11C]SCH23390 | 17 (10/7)             | 18         | <b>\</b>                     |
| Karlsson et al.,<br>2002 | [11C]SCH23390 | 10 (10/0)             | 10         | No change                    |
| Hirvonen et al.,<br>2006 | [11C]SCH23390 | (0/9)                 | (11/13)    | ↑ Disc Twins  ↓ MedicatedSCZ |
| Abi-Dargham et all, 2002 | [11C]NNC112   | 16 (9/7)              | 16         | <b>↑</b>                     |
| Abi-Dargham et all, 2009 | [11C]NNC112   | 25 (12/13)            | 40         | ↑ In DN<br>No change in DF   |

# Imaging cortical DA release with [11C]FLB457/ amphetamine paradigm/ multimodal imaging




fMRI imaging session: N back, SOT, resting state connectivity Behavioral tests outside of the scanner



Slifstein et al, JAMA Psychiatry 2015


# Generalized deficit in dopamine release capacity in SCZ SCZ =20, HC = 21



Regional Averages in displacement of radiotracer ± SD


Slifstein et al, JAMA Psychiatry 2015

## **Self-Ordered Working Memory Task**






## **WM Performance**




# D2 levels in DLPFC predict Working Memory performance in HC



Slifstein et al, JAMA Psychiatry 2015

## **Neuroimaging of DLPFC Function in SCZ**



#### Article

#### **Complexity of Prefrontal Cortical Dysfunction** in Schizophrenia: More Than Up or Down

Joseph H. Callicott, M.D. Venkata S. Mattay, M.D.

Beth A. Verchinski, B.S.

Michael F. Egan, M.D.

some studies find too little activation and patients. others too much. The authors' goal was to explore this phenomenon.

Method: They used the N-back working memory task and functional magnetic healthy subjects.

jects. However, there were areas within subjects and patients with high or low cortex.

Objective: Numerous neuroimaging performance, locales of greater prefrontal studies have examined the function of activation and locales of less activation the dorsolateral prefrontal cortex in were found in the high-performing schizophrenia; although abnormalities patients but only locales of underactivausually are identified, it is unclear why tion were found in the low-performing Conclusions: These findings suggest that

patients with schizophrenia whose nerformance on the N-back working memory resonance imaging at 3.T to examine a group of 14 patients with schizophrenia task is similar to that of healthy comparison subjects use greater prefrontal reand a matched comparison group of 14 sources but achieve lower accuracy (i.e., inefficiency) and that other patients with schizophrenia fail to sustain the prefron-Results: Patients' performance was signature of the second nificantly worse on the two-back working tion, achieving even lower accuracy as a result. These findings add to other evithe dorsolateral prefrontal cortex of the dence that abnormalities of prefrontal patients that were more active and areas cortical function in schizophrenia are not that were less active than those of the reducible to simply too much or too little healthy subjects. When the groups were activity but, rather, reflect a compromised subdivided on the basis of performance neural strategy for handling information on the working memory task into healthy mediated by the dorsolateral prefrontal

(Am J Psychiatry 2003; 160:2209-2215)


## Hypofrontality **Patients** Comparison subjects

Shared

Patients and Comparison Subjects on Same Curve


Working Memory Load

#### Patients and Comparison Subjects on Distinct Curves



Working Memory Load


# Mechanisms of WM Dysfunction in SCZ



P < 0.05, Alphasim extent thresholded; DLPFC ROI in shaded region

# Dopamine release predicts working-memory performance


Schizophrenia



Schizophrenia (n=10)

 $\beta = 0.64$ 


p = 0.046



Haber and Mc Farland, Ann N Y Acad Sci.1999, Kegeles et al, Archives of Gen Psychiatry, 2010 Howes et al, Archives of Gen Psychiatry 2009, Slifstein et al, JAMA Psychiatry, 2015

## OUTLINE


- The Hypothesis
- The Evidence
  - Confirming the hypothesis
  - Refining the hypothesis
  - Expanding the hypothesis: extrastriatal deficit, midbrain deficit?
- The Model(s)
  - Is dopamine dysregulation a downstream effect of other more upstream events?
  - Or could it be more proximal than generally thought?



## OUTLINE

- The Hypothesis
- The Evidence
  - Confirming the hypothesis
  - Refining the hypothesis
  - Expanding the hypothesis
- The Model(s)
  - Is dopamine dysregulation a downstream effect of other more upstream events?
  - Or could it be more proximal than generally thought?

## 108 independent loci exceeding criteria for GWAS significance These include D2 and other dopamine relevant genes





# What are the consequences of increased D2 signaling during development?

Transgenic D2OE: increase D2 by 15% in dorsal striatum to examine effects of increased D2 signaling on brain function and structure



# Overexpression of D2Rs in the Striatum Leads to Deficits In Cognition And Motivation

1) Non reversible Deficit in prefrontal dependent cognition

(Kellendonk, Simpson et al. 2006 Neuron, Bach et al. 2008 PNAS, Ward et al. 2009 Behavioral Neuroscience

2) Reversible Deficit in incentive motivation (negative symptom)


(Drew et al. 2007 J. Neuroscience, Simpson et al. 2011 Biological Psychiatry, Ward et al. 2012 Neuropsychopharmacology)


How does the increased D2 signaling in striatum affect prefrontal dependent cognition?

Increased DA turnover CTX (Kellendonk, Simpson et al. 2006 Neuron) Decreased firing of VTA DA cells, due to decreased expression of NMDA receptors (Krabbe et al, PNAS 2015) And even changes in anatomical collateral projections within basal ganglia:

C. Kellendonk

## Bi-directional Modulation Of Bridging Collaterals By Dopamine D2 Receptors





Dysregulation of presynaptic dopamine


Adulthood

**Clinical syndrome** 

## Emerging questions and Future directions

- Does the dual phenotype (striatal excess, extrastriatal deficit) exist at a single patient level?
- Which is primary?: D2 vs presynaptic DA dysfunction, striatal vs extrastriatal?
- Can the global « deficit »: pancortical, amygdala, hippocampus, thalamus, midbrain, explain the different domains of pathology?
- How does this affect learning and translate into symptoms?
- Our treatments do not address this complexity!
- We need to understand the cellular mechanisms and consequences to develop better treatments

#### Potential cellular mechanisms for striatal DA dysregulation



#### [18F]f-DOPA:

More transport of fdopa into cell: AAT More synthesis: Tyr H or AADC activity

More storage: VMAT

Less metabolism: COMT or MAO

Specific problem with the D2 autoreceptors only in striatum: no feedback on the subset

of cells that is overactive Number of DA neurons

**Excess firing activity of a subset of DA** 

neurons

### **Amphetamine or AMPT:**

More vesicles
Abnormal DAT function: "leaky" DAT and more synthesis to compensate?
D2 shifted intrasynaptically
D2 more sensitive to DA
ACH enhancement of DA release is abnormal

....

## Amphetamine-induced DA release in schizophrenia (striatum as a whole) [123I]IBZM displacement (%baseline) 50% **Amphetamine-induced** 40% 30% •• 20% 10% 0% p = 0.001SCH

n = 34

 $17 \pm 13\%$ 

n = 36

 $7 \pm 7\%$ 

Laruelle, PNAS, 1996 Abi-Dargham, AJP, 1998



### **Division of Translational Imaging**

**Conte Center** 

Mark Slifstein PhD Roberto Gil, MD Larry Kegeles, MD, PhD Ragy Girgis, MD

Guillermo Horga, MD Jared Van Snellenberg, PhD Cliff Cassidy, PhD

> Jodi Weinstein, MD Gary Brucato, PhD Xiaoyan Xu PhD

Elizabeth Hackett /Rawad Ayoub/ Najate Ojeil Rachel Rosenfield/ Juan Sanchez/Seth Baker

Yale collaborators: Cyril D' Souza, Robert Malison, Richard Carson, Henry Huang, Nabeel Nabulsi Eric Kandel, MD, PhD
Jonathan Javitch MD, PhD
Jeff Lieberman MD
Holly Moore, PhD
Steve Rayport, MD, PhD
Daphna Shohamy, PhD
Eleanor Simpson, PhD
Christoph Kellendonk, PhD

Rochester U: Suzanne Haber, PhD

Marc Laruelle, MD



Funding: NIMH, NIDA, NARSAD